自1985年Rosenberg等[1]首次报道临床应用过继性免疫疗法以来，国内外学者做了大量工作，普遍认为联合适当的全身化（放）疗可提高疗效和减轻毒副反应[2]。我们对42例癌性胸液病人做了前瞻性研究，比较三种免疫化疗的临床近期疗效，试图对免疫化疗的实施及应用价值作一初步探讨 Since Rosenberg et al. [1] reported for the first time in clinical application of adoptive immunotherapy in 1985, scholars at home and abroad have done a lot of work. It is generally believed that combined with proper systemic therapy can improve the efficacy and reduce toxic and side effects [2]. We conducted a prospective study of 42 patients with cancerous pleural fluid, compared the clinical short-term efficacy of three immunochemotherapy, and tried to discuss the implementation and value of immunochemotherapy.